Sangamo Therapeutics, Inc. filed amended July and August monthly operating reports and a September report for its bankruptcy case; its common stock was delisted effective October 17, 2026.
SGMOQ · Sangamo Therapeutics, Inc · Documents
Substantial doubt about the company's ability to continue as a going concern.
“Our history of significant losses, negative cash flows from operations, negative working capital, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management's assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued.”View the 10-Q filed May 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Sangamo Therapeutics filed its monthly operating report for August 2026 in its Chapter 11 case. It reported a net loss of -14,449,029 (cumulative -29,369,386), cash receipts of 10,145,433, disbursements of 3,826,691, and an ending cash balance of 23,225,696.
Sangamo Therapeutics completed the sale of ST-920-related assets to PTC Therapeutics for $111,000,000 in cash at closing plus up to $100,000,000 in contingent consideration; Nasdaq delisting becomes effective September 27, 2026.